NasdaqGM - Nasdaq Real Time Price • USD
Omeros Corporation (OMER)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:48 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 2 |
| Avg. Estimate | -0.58 | -0.56 | -2.23 | -1.79 |
| Low Estimate | -0.62 | -0.62 | -2.5 | -2.5 |
| High Estimate | -0.53 | -0.43 | -1.69 | -1.09 |
| Year Ago EPS | -0.54 | -0.59 | -1.88 | -2.23 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 2 |
| Avg. Estimate | -- | -- | 16.67M | 6.5M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 50M | 13M |
| Year Ago Sales | -- | -- | -- | 16.67M |
| Sales Growth (year/est) | -- | -- | -- | -61.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.56 | -0.57 | -0.61 | -0.55 |
| EPS Actual | -0.54 | -0.59 | -0.6 | -0.15 |
| Difference | 0.02 | -0.02 | 0.01 | 0.4 |
| Surprise % | 3.60% | -3.50% | 1.60% | 72.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.58 | -0.56 | -2.23 | -1.79 |
| 7 Days Ago | -0.58 | -0.56 | -2.23 | -1.79 |
| 30 Days Ago | 0 | 0 | -1.78 | -1.54 |
| 60 Days Ago | 0 | 0 | -1.78 | -1.54 |
| 90 Days Ago | 0 | 0 | -1.78 | -1.54 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | OMER | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -7.40% | -- | -- | 1.60% |
| Next Qtr. | 5.10% | -- | -- | 10.50% |
| Current Year | -18.60% | -- | -- | 5.20% |
| Next Year | 19.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 85.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Cantor Fitzgerald: Overweight to Neutral | 11/10/2023 |
| Downgrade | UBS: Buy to Neutral | 12/8/2022 |
| Downgrade | B of A Securities: Neutral to Underperform | 11/8/2022 |
| Downgrade | B of A Securities: Buy to Neutral | 6/8/2022 |
| Maintains | HC Wainwright & Co.: Buy | 10/19/2021 |
| Downgrade | JP Morgan: Neutral to Underweight | 10/8/2021 |
Related Tickers
OABI OmniAb, Inc.
4.6700
+1.74%
AVXL Anavex Life Sciences Corp.
3.7800
-0.53%
KPTI Karyopharm Therapeutics Inc.
1.1700
-8.59%
LYEL Lyell Immunopharma, Inc.
2.2300
-4.29%
OMGA Omega Therapeutics, Inc.
2.4000
-0.83%
OCUL Ocular Therapeutix, Inc.
5.22
-10.92%
RLMD Relmada Therapeutics, Inc.
4.0000
-6.98%
LRMR Larimar Therapeutics, Inc.
6.53
+2.35%
SGMO Sangamo Therapeutics, Inc.
0.5115
+5.44%
RYTM Rhythm Pharmaceuticals, Inc.
38.01
-0.26%